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In this commentary, we respond to the
conclusions of recent publications by
Hopenhayn-Rich et al. (1) and Smith et al.
(2) regarding issues of arsenic risk assess-
ment. Although Hopenhayn-Rich et al.
was not published in EnvironmentalHealth
Perspectives, we believe that it is important
to examine these studies and their rele-
vance to risk assessment together.
In 1988 the Risk Assessment Forum of
the U.S. Environmental Protection Agency
developed a cancer slope factor (CSF; the
U.S. EPA estimate of carcinogenic poten-
cy) for arsenic based on an ecological epi-
demiology study relating skin cancer to
arsenic ingestion in Taiwan. Several impor-
tant questions have been raised about this
CSF. One issue with this CSF is that it
assumes a linear dose-response relationship
for cancer, and thus it does not reflect
increasing evidence indicating either a
threshold or a sublinear dose-response
relationship for low doses of arsenic (3,4).
[Saturation of the methylation detoxifica-
tion pathway has been proposed as one
explanation for the sublinear dose-
response relationship for arsenic (5).]
Another issue is whether ingestion of
arsenic is associated with cancers other
than skin cancer.
EPA is currently under a judicial man-
date to evaluate whether the existing maxi-
mum contaiminant level (MCL) should be
revised (the current MCL is 50 pg/l). In
evaluating the existing MCL and the possi-
ble need for a revised MCL, EPA will likely
consider recent publications regarding the
issues of the methylation threshold and
internal cancers. Two recent publications
[Hopenhayn-Rich et al. (1) and Smith et
al. (2)] are seemingly pertinent to these
issues; however, as described below, we
found that these publications have defi-
ciencies that limit their applicability to
these regulatory questions. The studies
used by Hopenhayn-Rich et al. were not
designed appropriately to address the
methylation threshold issue. The paper by
Smith et al. failed to address a variety of
significant uncertainties that call into ques-
tion their risk assessment model.
Hopenhayn-Rich et al.
Methylation is generally accepted as a
metabolic detoxification mechanism for
low doses of inorganic arsenic (5).
Hopenhayn-Rich et al., however, question
the conclusion of the EPA Science
Advisory Board that "at dose levels below
200 to 250 pg As3/person/day [where
metabolic saturation begins] there is a pos-
sible detoxification mechanism (methyla-
tion) that may substantially reduce cancer
risk from the levels EPA has calculated"
(5). Using data from previously published
studies, Hopenhayn-Rich et al. used per-
cent inorganic arsenic in urine as a measure
of non-detoxified arsenic and total urinary
arsenic concentration as a measure of
arsenic dose and applied simple linear
regression to determine whether the per-
centage of inorganic arsenic increases with
increasing dose. Their results failed to
show a correlation between percent inor-
ganic arsenic and urinary arsenic concen-
tration and, on that basis, the authors con-
cluded that there is no consistent evidence
to support the methylation threshold
hypothesis in humans.
The Hopenhayn-Rich et al. evaluation
does not, however, demonstrate the ab-
sence of a methylation threshold for the
following reasons:
- The average arsenic exposures in
almost all of the studies analyzed were too
low to observe methylation saturation.
Evidence from the study by Buchet et al.
(6) suggests that methylation would be
completely saturated at exposures greater
than 500 pg/day, with corresponding total
urinary arsenic output of approximately
290 pg/day at steady state. If average daily
urine output is 1.51/day (1), this is equiva-
lent to an average urinary arsenic concen-
tration of about 190 pg/l. Among the 28
populations analyzed by Hopenhayn-Rich,
only two populations (7,8) had average uri-
nary arsenic concentrations at or above 190
pg/l (238 and 245 pg/I, respectively); a
regression analysis on the individual data
within the Yamauchi et al. (7) population
was borderline significant atp = 0.10 [indi-
vidual data were not available for the
Farmer andJohnson population (8)].
* The authors used urinary arsenic con-
centrations from grab samples as the basis
for evaluating methylating capacity.
However, the proportion of inorganic
arsenic excreted in the urine varies substan-
tially over time; thus, an individual grab
sample is not representative of the degree
ofmethylation that is occurring. Studies by
Buchet et al. (6) show that after ingestion
of inorganic arsenic, the proportion of
arsenic in the urine that is inorganic
arsenic is high soon after exposure (0-12
hr), but much lower later on (>12 hr).
The appropriate measurement with which
to examine metabolism and elimination of
arsenic is the total mass of inorganic
arsenic and its metabolites eliminated over
a 24- to 48-hr time period; using mass per
time rather than concentration would
control not only for variability in the pro-
portions of the metabolites over the
course of a day, but also for variability in
urine volume. A recent 7-day diet study in
Japan found that the intake and excretion
of total arsenic were balanced when aver-
aged over a week but not over 1 day (9).
Smith et al.
Currently, the CSF for ingested arsenic is
based on the incidence of nonmelanoma
skin cancers associated with exposure to
high levels of arsenic in drinking water in
Taiwan; however, Smith et al. have sug-
gested that arsenic could be an important
risk factor not only for skin cancer, but
also for several internal cancers including
lung, liver, bladder, and kidney. Smith et
al. used the data from another epidemio-
logical study in Taiwan (10) to examine
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whether there might be an association
between ingested arsenic and internal can-
cers [these data are described in greater
detail in a more recent epidemiological
study in Taiwan (11)]. The authors
applied simple linear regression to data
from the Taiwanese study and found a lin-
ear relationship between well water con-
centrations of arsenic and mortality rates
for liver, lung, kidney, and bladder cancer.
The U.S. lifetime risk of cancer due to
consuming 1 I/day ofdrinking water con-
taining 50 pg/I arsenic was estimated by
Smith et al. to be 13/1000 (2: Table 5).
This risk may be converted to a CSF of 18
(mg/kg-day)'l for administered dose,
which is approximately 10 fold higher than
the current CSF of1.75 (mg/kg-day)'.
-We noted the following deficiencies in
the analysis of Smith et al., particularly in
relation to risks in U.S. populations:
* In deriving risk estimates associated
with arsenic exposure using linear regres-
sion, Smith et al. assumed that the arsenic
intake of the control population was zero.
This assumption is unrealistic given other
sources of arsenic in the diet and would
inflate the CSF byartificially increasing the
slope ofthe exposure-response curve.
* Smith et al. did not discuss the impli-
cations of detoxification in estimating
potential risks from low-level exposures
typical ofthe U.S. population (an estimate
of typical U.S. background exposure is
about 22 pg/day). The estimated exposure
level of22 pg/day As for the U.S. popula-
tion is substantially lower than an estimat-
ed 2130 pg/day As for the Taiwan study
population [based on a concentration of
0.47 mg/l As in drinking water (12,13)
and assuming a water consumption rate of
4.5 I/day and 18 pg/day As in food, using
the most current EPA arsenic intake esti-
mates for Taiwan (14)]. As noted above,
the EPA Science Advisory Board recom-
mends that arsenic detoxification be con-
sidered in the risk assessment ofexposures
below 200-250 pg/day (5). This recom-
mendation represents a level below which
methylation is not compromised.
According to Buchet et al. (6), saturation
of methylation begins at this level and is
complete at levels greater than 500 pg/day.
* Smith et al. did not consider key
uncertainties in the use ofthe Taiwan data
in their analysis. For example, blackfoot
disease and bladder cancers are associated
with fluorescent humic acids found in the
Taiwanese drinking water (15,16). The
potential role of humic acids in bladder
cancer etiology (or other cancer types)
makes conclusions regarding any quantita-
tive association between arsenic and cancer
uncertain. In addition, it may render the
extrapolation from Taiwanese expos-
ure-response data to risks from arsenic in
drinking water in the U.S. questionable.
This may be an important consideration
not only for evaluating the paper ofSmith
et al., but possibly for evaluating the validi-
ty ofthe present CSF.
* Smith et al. did not address (nor does
the current CSF) the differences between
the Taiwanese and U.S. populations that
would reduce the accuracy of using expo-
sure-response data from Taiwan for U.S.
populations. For example, the average pro-
tein intake (which would influence the
extent of detoxification of arsenic) in the
blackfoot disease endemic area was only
65% of the current average U.S. protein
intake, potentially compromising the
detoxification of arsenic and invalidating
the CSF for use in U.S. populations.
Average protein intake in the blackfoot dis-
ease endemic area in 1975 was 44.1 g/day
in women and 65.3 g/day in men (17;
Guo H-R, personal communication); aver-
age U.S. protein intake is 65-70 g/day in
women and 90-110 g/day in men (18).
Additionally, the intake ofmethionine (an
amino acid necessary for arsenic methyla-
tion) (10) plus cystine was very low in the
endemic area [1.2 g/day (15)] compared to
the average U.S. intake [2.3-2.5 g/day in
women and 3.2-3.9 g/day in men (16)]. In
fact, the intake of methionine alone was
deficient; the average intake was 70% of
the recommended daily minimum (17;
Guo H-R, personal communication).
The exposure parameters for the
Taiwan study that were used by Smith et
al. may have biased the cancer risk esti-
mate. EPA recently approved a reference
dose (RfD) for arsenic (using the Tai-
wanese data) that uses a water consump-
tion rate for males and females combined
of4.5 1/day (14), as compared to thevalues
of 3.5 and 2 1/day for males and females,
respectively, used by Smith et al. In addi-
tion, the RfD derivation assumed a back-
ground dietary arsenic intake of 2 pg/day
(18), based on estimates from Taiwan of
30 pg As/kg in rice and a daily rice con-
sumption of0.225 kg, and the assumption
(from an FDA survey) that 35% ofarsenic
in rice was inorganic. In contrast, Smith et
al. assumed that the background intake in
Taiwan was zero. Consequently, CSFs cal-
culated using the revised EPA exposure
parameters would be significantly lower
than those calculated by Smith et al. [We
also note that use of the revised exposure
parameters would also decrease EPA's pre-
sent CSF for skin cancer (19)].
In summary, the Smith et al. and
Hopenhayn-Rich et al. analyses are flawed.
Hopenhayn-Rich et al. do not provide a
basis for dismissing the methylation
threshold hypothesis as the basis for the
apparent lack of carcinogenicity of arsenic
at low levels. We recommend that arsenic
regulation should not consider any
dose-response relationship between arsenic
and internal cancers based on the Smith et
al. analysis because of the deficiencies dis-
cussed above. Mechanistic or more refined
epidemiological studies are needed to assess
the possible relationship between internal
cancers and arsenic ingestion. An example
ofsuch a study is provided by a recent epi-
demiological study conducted in Taiwan
which found no consistent association
between the arsenic level in well water and
urinary cancer incidence with arsenic levels
less than 0.32 ppm and a statistically sig-
nificant association between arsenic and
bladder cancer at levels greater than 0.64
ppm, thus indicating a possible nonlinear
dose-response relationship between arsenic
exposure and urinary cancer (20). In addi-
tion, a similar association was also observed
for transitional cell renal cancer, but not
renal cell renal cancer. It should be noted
that this study involved approximately 11
million individuals residing in 243 town-
ships and used 10 exposure groups. This
contrasts with the study used by EPA to
derive the current CSF, which involved
approximately 40,000 individuals in 37
villages, using only 3 exposure groups
(12,13). Furthermore, we recommend that
future risk assessments for arsenic consider
evidence for a sublinear arsenic-induced
cancer dose-response relationship, as rec-
ognized by the EPA's Science Advisory
Board (J0).
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